The global burden of end-stage kidney disease (ESKD) has increased dramatically over the last 2 decades. Globally 2.5 million people receive dialysis for ESKD; however, outcomes for these patients are still poor. Therapies that improve outcomes in the dialysis population are urgently needed.Cardiovascular disease, particularly heart failure, is the leading cause of death in dialysis patients. In the general population the use of mineralocorticoid antagonists, such as spironolactone, have been shown to reduce mortality and hospital admissions. However, this standard therapy is rarely used in patients with ESKD.The ACHIEVE study is a multicentre double-blinded randomised, controlled trial that examines the effect of spironolactone (an aldosterone antagonist) compared to placebo. It will determine whether Spironolactone decreases cardiovascular death and heart failure in dialysis patients. This is an international collaboration with the Population Health Research Institute (based in Canada). To date, 2,477 patie

Millions of Australians and hundreds of millions of people around the world suffer from conditions caused by excessive consumption of unhealthy foods and insufficient intake of healthy foods. The food system is one of the largest contributors to environmental degradation through greenhouse gas emissions, water use and deforestation, and one of the sectors hardest hit by climate change. Access to information about the nutritional quality and environmental impacts of the food we eat is a basic consumer right, yet is lacking.  The Healthy Food, Healthy Planet, Healthy People Centre for Research Excellence will deliver world-leading innovations in nutrient profiling algorithms and environmental indicators that estimate the human and planetary consequences of varying patterns of food and beverage consumption. The project will: Identify effective means of conveying combined nutrition and sustainability information. Use the developed algorithms, environmental indicators and user response data